



Androgenic Agents

Therapeutic Class Review (TCR)

March 2, 2015

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
10101 Alliance Road, Suite 201
Cincinnati, Ohio 45242

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCReEditor@magellanhealth.com.

FDA-APPROVED INDICATIONS

Drug	Manufacturer	Indications
testosterone gel (AndroGel®) ^{1,2}	generic, Abbvie	Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, such as primary or secondary hypogonadism (congenital or acquired)
testosterone gel (Fortesta™) ³	generic, Endo	
testosterone gel (Testim®) ⁴	generic, Auxilium	
testosterone gel (Vogelxo®) ⁵	generic, Upsher-Smith	
testosterone solution (Axiron®) ⁶	Lilly	
testosterone transdermal system (Androderm®) ⁷	Watson	

OVERVIEW^{8,9}

Male hypogonadism is caused by insufficient production of testosterone and characterized by low serum concentrations. Hypogonadism may present as testosterone deficiency, infertility, or both.¹⁰ Symptoms at presentation will primarily depend on the patient's age at the time of disease onset and can include impotence, decreased libido, fatigue, loss of energy, mood depression, and regression of secondary sex characteristics. Potential risks due to male hypogonadism include osteoporosis, sexual dysfunction, depression, and cardiovascular disease. Approximately 20 percent of men ages 60 to 69 years old and 30 percent of men ages 70 to 79 years old have serum testosterone levels below the normal range.¹¹

Causes of hypogonadism are classified as primary, due to failure of the testes, or secondary, due to failure of the hypothalamus or pituitary gland. Either type of hypogonadism, may be caused by an inherited (congenital) or acquired factor. Conditions resulting in primary male include hypogonadism include cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, chemotherapy, radiation therapy, toxic damage from alcohol or heavy metals, testicular infections (such as mumps) and chromosomal abnormalities such as Klinefelter's Syndrome. Patients usually present with low testosterone levels and elevated follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels. Secondary (hypogonadotropic) hypogonadism includes idiopathic gonadotropin or luteinizing hormone releasing hormone (LHRH) deficiency and pituitary hypothalamic injury from tumors, trauma, or radiation. Testosterone levels are low in patients with secondary hypogonadism, but FSH and LH levels are low or in the normal range.

Testosterone levels are associated with a diurnal rhythm; the highest levels occur during the early morning hours. The testes produce 6–7 mg of testosterone daily, resulting in normal circulating testosterone levels ranging from 300 to 1,000 ng/dL. Testosterone supplementation can maintain secondary sex characteristics, optimize bone density, and restore fertility. Oral administration of testosterone is ineffective due to first-pass metabolism in the liver, so injectable and transdermal methods of delivery are ideal. Transdermal delivery of testosterone is appealing to some patients as it is convenient to use and eliminates frequent office visits often required by injectable testosterone.

The 2002 Treatment guidelines for hypogonadism published by the American Association of Clinical Endocrinologists do not list a preferred method of delivery for testosterone replacement.¹² The 2010 Endocrine Society treatment guidelines for androgen deficiency syndromes recommend testosterone therapy for symptomatic men with classical androgen deficiency syndromes aimed at inducing and maintaining secondary sex characteristics and at improving their sexual function, sense of well-being, and bone mineral density.¹³ The guidelines suggest initiating testosterone therapy using testosterone patches or gel, bioadhesive buccal tablets, injectable testosterone enanthate or cypionate or implanted pellets chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. The guidelines cite frequent skin reactions at application site as a potential adverse event for testosterone patch formulations. They cite skin irritation and testosterone transfer to another person who is in close contact as a potential adverse event for the transdermal gel formulations. The guidelines recommend against testosterone therapy in patients with breast or prostate cancer. They recommend against testosterone therapy without further urological evaluation in patients with palpable prostate nodule or induration or prostate specific antigen (PSA) 4 ng/mL or PSA 3 ng/mL in men at high risk of prostate cancer, such as African Americans or men with first-degree relatives with prostate cancer. The guidelines also recommend against testosterone treatment in patients with hematocrit greater than 50 percent, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms associated with benign prostatic hypertrophy, and uncontrolled or poorly controlled congestive heart failure.

Treatment goals are continuation of normal activities of daily living and decreased risk of secondary complications such as infertility, osteoporosis, fatigue, and mood disturbances.

PHARMACOLOGY^{14,15,16,17,18,19,20}

Topical androgens deliver physiologic amounts of testosterone to the patient, producing testosterone levels correlating with concentrations seen in healthy men. Testosterone is bound in the serum to sex hormone-binding globulin (SHBG) and albumin. Approximately 40 percent of testosterone in plasma is bound to SHBG and is not biologically active. In addition, SHBG production increases with age, so increasing amounts of testosterone will be bound as men age. Two percent of testosterone is unbound, and the remainder is bound to albumin. The portion bound to albumin is considered to be biologically active since it freely dissociates from albumin.

In many tissues, the activity of testosterone depends on the conversion to dihydrotestosterone (DHT). DHT binds to cytosol receptor proteins; this complex initiates androgenic actions in cell nuclei. DHT is further metabolized to 3 α - and 3 β -androstenediol.

PHARMACOKINETICS

Drug	Tmax (hours)	Cavg (ng/dL)	t1/2 (minutes)
testosterone gel (AndroGel 1%) ²¹	2	566–792	10–100
testosterone gel (AndroGel 1.62%) ²²	8	386–643	10–100
testosterone gel (Fortesta) ²³	4	415–964*	10–100
testosterone gel (Testim) ²⁴	4–8	365–612	10–100
testosterone gel (Vogelxo) ²⁵	4–8	365–612	10–100
testosterone solution (Axiron) ²⁶	2	456–480	10–100
testosterone transdermal (Androderm) ²⁷	4–12	300–1030	10–100

*reported for 40-70 mg doses.

Bioavailability of each product is variable, but most report absorption rates of approximately 10 percent. One small study found testosterone gel preparations (AndroGel, Testim) not bioequivalent; Testim provided higher serum levels than AndroGel when equivalent dosing was used.²⁸

Information regarding the excretion of testosterone is only available for intramuscular administration. By this route, 90 percent of a dose is excreted in the urine as metabolites, and six percent appears unchanged in the feces.

CONTRAINDICATIONS/WARNINGS^{29,30,31,32,33,34,35}

All the gel and solution products listed (AndroGel 1%, AndroGel 1.62, Axiron, Fortesta, Testim, and Vogelxo) carry a boxed warning on virilization of children following secondary exposure. The boxed warning does not presently include testosterone patches, although women and children are cautioned to avoid exposure.

Use of testosterone products is contraindicated in men with carcinoma of the breast or known prostate carcinoma. Testosterone products are Pregnancy Category X and should not be used or handled by women who are pregnant, may become pregnant, or are breastfeeding.

In May 2009, FDA issued a safety alert for testosterone gel products, AndroGel and Testim, due to eight reports of children experiencing adverse effects after unintended exposure to testosterone through contact with an individual being treated with these agents.³⁶ Virilization has been reported in children who were secondarily exposed to testosterone gel. All of the manufacturers of the testosterone gel and solution products are required to include a boxed warning in the medications' labels related to this safety issue.

Prolonged use of high doses of orally active 17-alkyl androgens such as methyltestosterone has been associated with severe hepatic adverse effects. Testosterone is not known to cause these effects.

Patients diagnosed with benign prostatic hyperplasia (BPH) and treated with androgens are at an increased risk for worsening of signs and symptoms of the disease. Additionally, patients treated with androgenic agents are at increased risk for developing prostatic carcinoma. Surveillance for prostate cancer is also recommended in this population as well as other patients with risk factors.

Sleep apnea, gynecomastia, and edema with or without congestive heart failure are also possible.

All topical testosterone products should be applied according to the specific administration instructions contained in the application instructions. Products should be applied evenly and not to areas not specified for each product, such as genitals, abdomen, behind the knees, or other locations.

Laboratory values requiring periodic monitoring during testosterone therapy include hemoglobin/hematocrit, liver function, prostate specific antigen, cholesterol, high-density lipoprotein cholesterol (HDL-C), and serum calcium.

All testosterone products are Schedule III controlled substances.

The FDA is investigating the risk of stroke, myocardial infarction, and death in men taking FDA-approved testosterone products.³⁷ This is based on two recent studies that suggest an increased risk of cardiovascular events among men prescribed testosterone therapy. The FDA will communicate its recommendations when the evaluation is complete.³⁸

Androderm, AndroGel 1%, AndroGel 1.62%, Axiron, Fortesta, Testim, and Vogelxo all carry an updated warning citing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products. Patients who report or exhibit symptoms of pain, edema, warmth, and erythema in the lower extremity should be evaluated for possible DVT, while those presenting with acute shortness of breath should be evaluated for potential PE. If there is evidence or suspicion of a possible a venous thromboembolic event, topical testosterone therapy should be discontinued and appropriate VTE management initiated.

Risk Evaluation and Mitigation Strategy (REMS)

At this time, all products in this review, except testosterone patches (Androderm), require medication guides as a component of REMS, and to be provided to patients on testosterone therapy.

DRUG INTERACTIONS^{39,40,41,42,43,44,45}

Testosterone can cause reductions in blood glucose levels. Patients being treated with testosterone and insulin simultaneously may have lower insulin requirements.

Changes in anticoagulant activity have also been observed in patients receiving both anticoagulant medications and testosterone therapy. It is recommended that patients with concurrent therapy have more frequent monitoring of their prothrombin time (PT) and International Normalized Ratio (INR).

When administered with corticosteroids, testosterone may increase the incidence and extent of edema. Cautious use is advised in patients with hepatic or cardiac disease.

ADVERSE EFFECTS

Drug	Application Site Reaction	Headache	Acne	Hypertension	Gynecomastia	Increased Hemoglobin/Hematocrit
testosterone gel (Androgel) ⁴⁶	3-5.6	0-4	1-8			reported
testosterone gel (Androgel 1.62%) ⁴⁷	2.1	nr	≤2	2.1		
testosterone gel (Fortesta) ⁴⁸	16.1	nr	nr			
testosterone gel (Testim) ⁴⁹	2-4	1	<1	<1	0-1	
testosterone gel (Vogelxo) ⁵⁰	2-4	1	>1	1	0-1	
testosterone solution (Axiron) ⁵¹	7-8	5-6				4-7
testosterone transdermal (Androderm) ⁵²	17	<3	nr			

Adverse effects are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all inclusive. nr = not reported.

SPECIAL POPULATIONS^{53,54,55,56,57,58}

Pediatrics

Testosterone products have not been evaluated in pediatric patients. Androderm, Androgel, Axiron, Fortesta, Testim, and Vogelxo are not approved for use in patients less than 18 years of age. Exposure may result in acceleration of bone age and premature closure of epiphyses. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel products.

Pregnancy

The products in this review are Pregnancy Category X.

Geriatrics

Testosterone transdermal products have not included sufficient numbers of patients 65 years and older in controlled clinical studies to determine whether there is a difference in efficacy and safety from results seen in younger patients. There are an insufficient number of long-term safety studies to

assess whether there are variances in prostate cancer or cardiovascular risks between geriatric and younger patients.

DOSAGES

Drug	Dosing	Administration	Availability
testosterone 1% gel (AndroGel 1%) ⁵⁹	5 g daily, preferably in the morning (delivers 5 mg systemically). Dosing may be increased to 10 mg (by 2.5 mg increments)	Apply to clean, dry, intact skin of the shoulders and upper arms; do not apply to the genitals	2.5, 5 g packets (30 per package); 75 g pump (2 per package); dispenses 60 metered 1.25 g doses
testosterone 1.62% gel (AndroGel 1.62%) ⁶⁰	40.5 mg (1.25 g of gel) once daily. Dosing may be adjusted between 20.25 mg and 81 mg based on levels drawn at 14 and 28 days after start of therapy	Apply to clean, dry, intact skin of the shoulders and upper arms; do not apply to the genitals	1.25, 2.5 g packets (contains 20.25 mg or 40.5 mg testosterone, respectively; 30 packets); 75 g pump with 60 pump actuations delivering 20.25 mg of testosterone per actuation (1.25 g of gel)
testosterone gel (Fortesta) ⁶¹	Initiate at 40 mg once every morning. Dosing may be adjusted from 10 mg to 70 mg based on levels two hours after application at days 14 and 35 after start of last adjustment	Apply to clean, dry, intact skin of the front and inner thighs; do not apply to genitals or other parts of the body	In a 60 g canister with metered dose pump delivering 10 mg testosterone in 0.5 g gel per actuation (available in packages of 1, 2, or 3 canisters)
testosterone 1% gel (Testim) ⁶²	5 g daily, preferably in the morning (delivers 5 mg systemically)	Apply to clean, dry, intact skin of the shoulders and/or upper arms; do not apply to genitals or abdomen	5 g tubes (30 per package)
testosterone gel (Vogelxo) ⁶³	50 mg applied topically once daily at approximately the same time each day. Dosing may be adjusted to 100 mg once daily based on levels drawn at 14 days after start of therapy. The maximum dose is 100 mg daily.	Apply to clean, dry, intact skin of the shoulders and/or upper arms; do not apply to genitals or abdomen	In unit-dose tubes or packets containing 50 mg testosterone in 5 g of gel; or multiple-dose metered pumps delivering 12.5 mg of testosterone in 1.25 g of gel per actuation
testosterone solution (Axiron) ⁶⁴	Initiate at 60 mg once a day. Dosing may be adjusted 30 mg based on levels drawn two to eight hours after application at days 14 after start or last adjustment	Apply to clean, dry, intact skin of the axilla preferably at the same time every morning; do not apply to the genitals or other parts of the body	110 mL of topical solution in a metered dose pump; each pump delivers 30 mg of testosterone in 1.5 mL of solution; each bottle has an applicator top
testosterone transdermal (Androderm) ⁶⁵	4 mg daily (nightly)	Apply to clean, dry skin of the back, abdomen, upper arms, or thighs; do not apply to genitals, bony prominences, or parts of the body that may be subject to prolonged pressure due to sitting or sleeping;	2 mg patches (60 per carton); 4 mg patches (30 per carton)

		rotate sites every seven days	
--	--	-------------------------------	--

The old Androderm strengths (2.5 mg/day and 5 mg/day patches) have been discontinued and are no longer available. Abbvie plans to discontinue Androgel 1% pump in the near future. Androgel 1% packets and all Androgel 1.62% formulations will continue to be produced.

- The application sites and dosing recommendations among testosterone replacement products are not interchangeable. Label instructions must be strictly followed to ensure safety and efficacy in use of these products.
- The dosing and administration for Androgel 1% and Androgel 1.62% are not equivalent. Refer to the prescribing information and the table above for the correct dosing of each product.
- Wash hands after applying gels; allow administration area of the gel to dry for several minutes before dressing. Cover the application site once it is dry. Drug can be transferred to others through vigorous skin-to-skin contact. Should skin-to-skin contact with another person be anticipated, the application site should be washed prior to such contact.
- Do not swim or shower within two hours after application of Androgel 1.62%, Axiron, Testim, or Vogelxo for maximum benefit. Do not swim or shower within five hours after application of Androgel 1% to achieve maximum effect. Do not swim, shower, or wash the site of administration for Androderm transdermal testosterone for three hours following application.
- Caution should be exercised when using gel or solution formulations around open flames until the applications are completely dry.
- The occlusive backing of Androderm prevents sexual partners from coming into contact with active drug.
- Mild skin irritation with Androderm can be lessened by applying over-the-counter hydrocortisone cream following removal of the patch. Alternately, triamcinolone 0.1% cream may be applied to the skin beneath the drug reservoir of the patch. Use of ointments for this purpose may decrease testosterone absorption.
- Testosterone patches contain 9.7 mg testosterone (2 mg patch) and 19.5 mg (4 mg patch).
- Testosterone levels should be measured, typically fourteen days following initiation of therapy to determine dosage adjustments.
- Alcohol based products, including Androgel, Axiron, Fortesta, Testim, and Vogelxo are flammable. Patients should be advised to avoid smoking, fire or flame until the dose applied has dried.

CLINICAL TRIALS

Search Strategies

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this class. Studies included for analysis in the review were published in English, performed with human participants and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest

systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance. Many of the trials with agents in this class were performed in an open-label manner; introduction of bias must be considered when evaluating study findings.

The method of administration and associated monitoring makes it difficult to perform properly blinded studies with these drugs. Due to the lack of double-blind studies, open-label studies have been included; while these studies may produce accurate results, the study design should be taken into consideration.

testosterone gel (Fortesta)

Testosterone gel (Fortesta) was evaluated in a multicenter, 90-day open-label, non-comparative trial of 149 hypogonadal male subjects with body mass index (BMI) ≥ 22 kg/m² and < 35 kg/m² and 18-75 years of age (mean 54.5 years).⁶⁶ Patients were screened for a single serum total testosterone concentration of < 250 ng/dL or two consecutive serum concentrations < 300 ng/dL. A dose of 40 mg was applied daily to the thighs, with adjustments between 10 mg and 70 mg of testosterone based on serum testosterone levels taken two hours after application taken on days 14, 35, and 60. The primary endpoint was the percentage of subjects with a normal testosterone concentration, defined as ≥ 300 to ≤ 1140 ng/dL, at day 90. At day 90, 77.5 percent of patients had achieved a normal testosterone concentration, and no patient had a maximum testosterone concentration $\geq 2,500$ ng/dL on day 90.

testosterone gel (Axiron)

Testosterone gel (Axiron) was evaluated in a multicenter, open label, 120-day trial across 26 centers and including 155 hypogonadal male subjects.⁶⁷ The median age for all subjects was 53 years with an age range from 19-78 years. Patients were instructed to apply testosterone gel according to the prescribed manner and not to alter current grooming habits. Patients received an Axiron dose of 60 mg during the initial treatment stage on days one through 15, and 76.1 percent of patients achieved an average serum total testosterone level in the normal range, defined as 300 to 1,050 ng/dL. On day 45, doses were adjusted based on their average serum testosterone level, as measured on day 15. Dose adjustment occurred again on day 90, based on the testosterone level taken on day 60. On day 60, 84.8 percent of subjects had a normal average serum testosterone level. The study concluded on day 120, at which point 84.1 percent of patients experienced a normal average serum testosterone level.

testosterone gel (Vogelxo)

Testosterone gel (Vogelxo) was evaluated in a randomized, multicenter, multi-dose, active and placebo controlled 90-day trial involving 406 adult males with morning testosterone levels of ≤ 300 ng/dL.⁶⁸ The study was double-blind for the doses of testosterone gel and placebo, but open-label for the non-scrotal testosterone transdermal system. During the first 60 days, patients were equally randomized to receive either testosterone gel 50 mg, testosterone gel 100 mg, placebo gel, or testosterone transdermal system. At day 60 of the trial, patients receiving testosterone gel were either maintained at the same dose, or were titrated up or down within their treatment group, based on 24-hour averaged serum testosterone concentration levels previously obtained on day 30. Of 192 hypogonadal males in the trial who were appropriately titrated with testosterone gel and who had generated sufficient data for analysis, 74 percent achieved an average serum testosterone level within the normal range (300 to 1,000 ng/dL) by treatment day 90.

testosterone transdermal patch (Androderm)

Testosterone transdermal (Androderm new formulation) was evaluated in a comparative trial to evaluate dosing and titration of the new 2 mg/day and 4 mg/day systems in 40 males with hypogonadism in a clinic setting.⁶⁹ Mean age was 55 years (range 34 to 76 years). Patients had previously been stabilized on either Androderm 5 mg; AndroGel 2.5 g, 5 g, 7.5 g, 10 g; or Testim 2.5 g or 5 g daily prior to the trial. Testosterone transdermal was applied nightly at 2000 hours for 14 days. Dosing was titrated based on serum concentrations taken the morning of day eight. Of patients formerly receiving Androderm 5 mg/day (n=11) 10 subjects remained at the 4 mg/day dosing and one was titrated down to the 2mg/day dosing. At the 28-day mark, 97 percent of trial subjects had serum testosterone C_{avg} measurements within the normal range for the dosing period.

testosterone gel (AndroGel) and testosterone transdermal patch (Androderm)

Effects of 180 days of treatment with testosterone 1% gel (50 or 100 mg/day) compared to testosterone patch (5 mg/day, old formulation) on defined efficacy parameters were studied in 227 hypogonadal men.⁷⁰ The randomized, parallel group study was double-blinded with respect to gel dose and open-label for the patch group. In the gel groups, the dose was adjusted up or down to 75 mg/day on day 90 if serum testosterone concentrations were below or above the normal male range. No dose adjustment was made in the patch group. Sexual function and mood, as monitored by questionnaire, improved maximally on day 30 of treatment without differences across groups and were maintained for the duration of therapy. Mean muscle strength in the leg press exercise increased by 11–13 kg in all treatment groups by 90 days and did not improve further at the end of treatment. Moderate increases were also observed in arm/chest muscle strength. At 90 days of treatment, lean body mass increased more in the 100 mg/day gel group than in the 50 mg/day gel and patch groups (2.74 versus 1.28 versus 1.20 kg, $p=0.0002$). Beneficial effects were accompanied by anticipated increases in hematocrit and hemoglobin but without significant changes in lipid profile. Skin irritation was reported in 5.5 percent of subjects treated with gel and in 66 percent of subjects in the patch group.

testosterone gel (Testim) and testosterone transdermal patch (Androderm)

To compare the safety and efficacy of two doses of testosterone 1% gel (50 or 100 mg/day) and a testosterone patch (2 x 2.5 mg, old formulation), 208 men with confirmed low serum testosterone levels and associated signs and symptoms of hypogonadism were randomized and treated for 90 days.⁷¹ The study was double-blinded with respect to the gel dose and open-label for the patch group. Pharmacokinetic profiles were obtained, body composition measured, and mood and sexual function data recorded. Mean increases from baseline to 90 days in testosterone were 12.41, 6.54, and 3.82 nmol/L for the 100 and 50 mg gel groups and the patch ($p<0.05$), respectively. Both doses of gel significantly improved positive and negative mood over baseline; the patch did not ($p<0.05$). All three treatments increased lean body mass. At all sample times, both doses of gel significantly improved sexual performance, motivation, and desire, as well as spontaneous erections. The patch provided improvements from baseline at all sample times for sexual performance, motivation, and desire, but no statistically significant effect on spontaneous erections. Gel treatment was well tolerated, while patch treatment produced higher rates of application site reactions, resulting in greater study discontinuation.

Hypogonadal male subjects (n=406) reporting one or more symptoms of low testosterone were randomized in a double-blinded manner to testosterone 1% gel (50 and 100 mg/day) or placebo, and

an open-label manner to testosterone patch (two 2.5 mg patches, old formulation).⁷² Subjects on the testosterone gel could be titrated up or down at day 60 on the basis of their day 30 serum testosterone level. Primary end points evaluated at 30 and 90 days included significant changes in the frequency of intercourse, nighttime erections, and sexual desire measured on a Likert-type scale and calculated as a mean daily score. At day 30, a significant increase from baseline in sexual desire score was noted for those on 100 mg/day gel compared with those on 50 mg/day gel, patch, or placebo (1.2 versus 0.4, 0.7, and 0.4, respectively; $p < 0.0013$). A significant increase from baseline in the frequency of nighttime erections was also noted for those on 100 mg/day gel compared with those on 50 mg/day gel or placebo (51 versus 30, 26 percent, respectively; $p < 0.003$), as well as for the patch versus placebo ($p = 0.0278$). Finally, a significant increase from baseline in the frequency of intercourse was evidenced for those on 100 mg/day gel compared with those on patch or placebo. Similar results were seen for 100 mg/d testosterone gel at day 90 for sexual desire and nighttime erections versus placebo.

In a 90-day open-label study, pharmacokinetics and treatment effectiveness of testosterone 1% gel were compared at 50 and 100 mg/day to a testosterone patch (two 2.5 mg patches, old formulation) and placebo gel in 406 hypogonadal men.⁷³ Pharmacokinetic profiles were obtained, body composition was measured, and mood and sexual function were monitored. Gel treatments resulted in dose-dependent improvements in all pharmacokinetic parameters compared with the testosterone patch and placebo. Mean average concentrations at day 90 were 13.8, 17.1, 11.9, and 7.3 nmol/L for 50 mg/day gel, 100 mg/day gel, patch, and placebo, respectively. At day 90, the 100 mg/day treatment improved lean body mass by 1.7 kg and percentage of body fat by 1.2 percent; this was significantly greater than either patch or placebo ($p < 0.05$). Significant improvements in spontaneous erections, sexual desire, and sexual motivation were also evidenced with the 100 mg/day dose in comparison with placebo; the patch also had significant increases with the exception of spontaneous erections. No differences in positive or negative mood were seen between groups. The testosterone patch resulted in a high rate of application site reactions.

SUMMARY

Based on available data, there are no apparent differences in efficacy among the various products as all six medications cited produce increased levels of circulating testosterone. The gel and solution formulations of testosterone, however, do demonstrate a lower incidence of adverse reactions related to administration compared to the patches. Long-term studies that evaluate topical treatment options for hypogonadism are lacking. The 2010 Endocrine Society testosterone therapy guideline recommends selecting a testosterone regimen on the basis of the patient's preference, pharmacokinetics profile, treatment burden, and cost.

Vogelxo is the most recent entry in this class, while Androgel 1.62% is a newer strength available along with Androgel 1%. While they share the same active ingredient, Androgel 1% and Androgel 1.62% have separate prescribing information. Androderm transdermal testosterone has been reconfigured by the manufacturer to a transdermal system with a 20 percent lower dose of testosterone in a smaller patch than the previous formulation. The 2.5 mg/day and 5 mg/day patches have been replaced by 2 mg/day and 4 mg/day transdermal patches which are still intended for once daily use.

REFERENCES

- 1 Androgel [package insert]. North Chicago, IL; AbbVie; November 2014.
- 2 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; November 2014.
- 3 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 4 Testim [package insert]. Chesterbrook, PA; Auxilium Pharmaceuticals, Inc.; June 2014.
- 5 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 6 Axiron [package insert]. Indianapolis, IN; Lilly USA LLC; June 2014.
- 7 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 8 American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. *Endocr Pract.* 2002; 8(6):440-456. Available at: <https://www.aace.com/files/hypo-gonadism.pdf>. Accessed March 2, 2014.
- 9 Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010; 95(6):2536-59. Available at: <http://press.endocrine.org/doi/full/10.1210/jc.2009-2354>. Accessed March 1, 2015.
- 10 American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. *Endocr Pract.* 2002; 8(6):440-456. Available at: <https://www.aace.com/files/hypo-gonadism.pdf>. Accessed March 1, 2015.
- 11 Morales A, Tenover JL. Androgen deficiency in the aging male: when, who, and how to investigate and treat. *Urol Clin North Am.* 2002; 29(4):975-982.
- 12 American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. *Endocr Pract.* 2002; 8(6):440-456. Available at: <https://www.aace.com/files/hypo-gonadism.pdf>. Accessed March 1, 2015.
- 13 Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010; 95(6):2536-59.
- 14 Androgel [package insert]. North Chicago, IL; AbbVie; November 2014. <http://press.endocrine.org/doi/full/10.1210/jc.2009-2354r.2014>.
- 15 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; November 2014.
- 16 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 17 Testim [package insert]. Chesterbrook, PA; Auxilium Pharmaceuticals, Inc.; June 2014.
- 18 Axiron [package insert]. Indianapolis, IN; Lilly USA LLC; June 2014.
- 19 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 20 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 21 Androgel [package insert]. North Chicago, IL; AbbVie; November 2014.
- 22 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; November 2014.
- 23 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 24 Testim [package insert]. Chesterbrook, PA; Auxilium Pharmaceuticals, Inc.; June 2014.
- 25 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 26 Axiron [package insert]. Indianapolis, IN; Lilly USA LLC; June 2014.
- 27 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 28 Marbury T, Hamill E, Bachand R, et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. *Biopharm Drug Dispos.* 2003; 24(3):115-120.
- 29 Androgel [package insert]. North Chicago, IL; AbbVie; November 2014.
- 30 Testim [package insert]. Chesterbrook, PA; Auxilium Pharmaceuticals, Inc.; August 2013.
- 31 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 32 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 33 Axiron [package insert]. Indianapolis, IN; Lilly USA LLC; June 2014.
- 34 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; November 2014.
- 35 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 36 Available at: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm149346.htm>. Accessed March 1, 2015.
- 37 FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm>. Accessed March 1, 2015.
- 38 Morgentaler A, Miner M, Caliber M, et al. Testosterone therapy and cardiovascular risk: advances and controversies. *Mayo Clin Proc.* 2015; 90(2):224-251. Available at: http://www.mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_ft90_1_2.pdf.
- 39 Androgel [package insert]. North Chicago, IL; AbbVie; November 2014.
- 40 Testim [package insert]. Chesterbrook, PA; Auxilium Pharmaceuticals, Inc.; June 2014.
- 41 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 42 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 43 Axiron [package insert]. Indianapolis, IN; Lilly USA LLC; June 2014.
- 44 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; November 2014.
- 45 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 46 Androgel [package insert]. North Chicago, IL; AbbVie; November 2014.
- 47 Androgel 1.62 [package insert]. North Chicago, IL; AbbVie; November 2014.
- 48 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 49 Testim [package insert]. Chesterbrook, PA; Auxilium Pharmaceuticals, Inc.; June 2014.
- 50 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 51 Axiron [package insert]. Indianapolis, IN; Lilly USA LLC; June 2014.

-
- 52 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 53 Androgele [package insert]. North Chicago, IL; AbbVie; November 2014.
- 54 Testim [package insert]. Chesterbrook, PA; Auxilium Pharmaceuticals, Inc.; June 2014.
- 55 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 56 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 57 Axiron [package insert]. Indianapolis, IN; Lilly USA LLC; June 2014.
- 58 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 59 Androgele [package insert]. North Chicago, IL; AbbVie; November 2014.
- 60 Androgele 1.62 [package insert]. North Chicago, IL; AbbVie; November 2014.
- 61 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 62 Testim [package insert]. Chesterbrook, PA; Auxilium Pharmaceuticals, Inc.; June 2014.
- 63 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 64 Axiron [package insert]. Indianapolis, IN; Lilly USA LLC; June 2014.
- 65 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 66 Fortesta [package insert]. Malvern, PA; Endo Pharmaceuticals, Inc.; June 2014.
- 67 Axiron [package insert]. Indianapolis, IN; Lilly USA; June 2014.
- 68 Vogelxo [package insert]. Maple Grove, MN; Upsher-Smith Laboratories, Inc.; June 2014.
- 69 Androderm [package insert]. Parsippany, NJ; Watson Pharma, Inc.; June 2014.
- 70 Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. *J Clin Endocrinol Metab.* 2000; 85(8):2839-2853.
- 71 McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. *BJU Int.* 2003; 91(1):69-74.
- 72 Seftel AD, Mack RJ, Secrest AR, et al. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. *J Androl.* 2004; 25(6):963-972.
- 73 Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. *J Clin Endocrinol Metab.* 2003; 88(6):2673-2681.